Sökning: id:"swepub:oai:DiVA.org:liu-98251" >
GAD-alum treatment ...
GAD-alum treatment induces GAD-specific CD4 T cells in a phase III clinical trial
-
- Pihl, Mikael (författare)
- Linköpings universitet,Pediatrik,Hälsouniversitetet
-
- Axelsson, Stina (författare)
- Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet
-
- Cheramy, Mikael (författare)
- Benaroya Research Institute at Virginia Mason, Seattle, USA
-
visa fler...
-
- Reijonen, Helena (författare)
- Benaroya Research Institute at Virginia Mason, Seattle, USA
-
- Ludvgisson, Johnny (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Barn- och ungdomskliniken i Linköping
-
- Casas, Rosaura (författare)
- Linköpings universitet,Pediatrik,Hälsouniversitetet
-
visa färre...
-
(creator_code:org_t)
- 2013
- Engelska.
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- Glutamic Acid Decarboxylase (GAD)65 formulated in aluminium hydroxide (GAD-alum preserved insulin secretion in a phase II clinical trial in recent onset type 1 diabetes. GADalum treated patients up-regulated FOXP3 upon antigen recall at 21 and 30 months after treatment. A 4-year follow-up of the study revealed increased frequencies of both CD25+CD127+ and CD25hiCD127lo cells in treated patients after antigen recall. A subsequent european phase III trial was closed after 15 months after failing to reach primary outcome. We monitored antigen recall induced frequencies of memory, effector and regulatory T cells throughout the phase III trial. Antigen recall induced mainly CD25+CD127+, CD45RO+ and non-suppressive FOXP3loCD45RA- cells in GAD-alum treated patients. In addition, a population of activated FSChiSSChi cells was observed, enriched in CD25+CD127+, CD45RO+ and proliferating cells. GAD65-specific T cells determined by tetramer staining were induced by antigen recall in GAD-alum treated patients and were more frequent in the FSChiSSChi population. Additional doses of GAD-alum increased frequencies of CD25+CD127+, CD45RO+ and FSChiSSChi cells but had no effect on frequencies of CD25hiCD127lo. Our findings indicate that antigen recall after GAD-alum treatment primarily induces memory and activated T cells. In particular, GAD65-specific cells were mainly of a memory or activated phenotype. Additional doses of GAD-alum mainly affect memory T cell frequency and T cell activation.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- vet (ämneskategori)
- ovr (ämneskategori)